SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Zydus Lifesciences

BSE: 532321 20 Aug 2025
Healthcare
₹ 989
Zydus Lifesciences Limited specializes in Pharmaceuticals within the Healthcare sector.

Zydus Lifesciences - Share Price & Details

Market Cap
₹99,557
High /Low
1,220 / 795.0
Stock P/E
21.4
Book Value
₹238.0
Dividend Yield
1.11
ROCE
24.3
ROE
₹21.2
Face Value
1.0
PEG Ratio
11.3
EVEBITDA
₹13.4
Debt
3,213
CMP / FCF
32.7
Debt to equity
₹0.13
NP Ann
4,673
High price all time
1,324
Piotroski score
₹7.0
Graham Number
493.0
No. Eq. Shares
101.0
Net CF
₹414
Net profit
4,711
Price to book value
4.16
Interest Coverage
₹29.7
Low price all time
25.5
Industry PE
33.5
Reserves
₹23,852
Free Cash Flow
₹5,116

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
Zydus Lifesciences Limited27454.03847.025883.03.8299,55721.4
LUPIN LTD.57627.321280.757085.946.488928024.1
FORTIS HEALTHCARE LTD.4730.4518.84330.30.697170377.9

Peer Comparison Chart


About Zydus Lifesciences

Zydus Lifesciences Limited, with Security Code 532321, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Zydus Lifesciences Q1 Review: Systematix Maintains Hold, Revises Target Price — Heres Why

(13 Aug 2025)
Zydus Lifesciences Ltd. Q1 FY26 revenues (Rs 65737 million) were in-line with estimates, but Ebitda (Rs 20885 million) and Net earnings (Rs...
Read more →

USFDA approves Zydus Lifesciences chronic idiopathic constipation drug Prucalopride

(12 Aug 2025)
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for...
Read more →

Zydus Lifesciences Limited Financial Performance for Q1 FY26

(12 Aug 2025)
Zydus Lifesciences Limited announced its unaudited consolidated financial results for the first quarter ended June 30th, 2025. Q1 FY26 Key Financial...
Read more →

Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz

(12 Aug 2025)
Ahmedabad-based Zydus Lifesciences on Tuesday reported a 5.9 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the June...
Read more →

Zydus Lifesciences Q1 net profit rises 3% to Rs 1,467 crore

(12 Aug 2025)
India Business News: Zydus Lifesciences on Tuesday said its consolidated net profit increased 3 per cent year-on-year to Rs 1467 crore for...
Read more →

Zydus Lifesciences Gains USFDA Nod for Diltiazem Hydrochloride Tablets

(11 Aug 2025)
Zydus Lifesciences Limited announced it has received final approval from the United States Food and Drug Administration (USFDA) for...
Read more →

Company Updates